The expanded reimbursement enables more access to FreeStyle Libre 2 for people living with diabetes in France. Credit: Abbott.

The French health authority has granted approval for the expansion of reimbursement coverage for Abbott’s FreeStyle Libre 2 continuous glucose monitoring (CGM) system.

Previously, the reimbursement for the CGM system was covered only for type 1 and type 2 diabetes patients who need intensive insulin therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The expanded reimbursement covers access to all individuals who use basal insulin as part of their diabetes management.

Abbott stated that this expansion enables more access to FreeStyle Libre 2 CGM for people living with diabetes in the country.

This marks the first European country to widen the national reimbursement for the FreeStyle Libre technology to basal insulin users.

It follows similar coverage expansions for the technology in the US Medicare system and Japan.

Abbott diabetes care business senior vice-president Jared Watkin said: “Our goal is to get our FreeStyle Libre technology to as many people as possible.

“The French national reimbursement decision is an important step in providing broader access to people with diabetes and we are working with other countries to extend this coverage to more people.”

The regulatory decision was based on the scientific evidence supporting the FreeStyle Libre system’s clinical benefits for insulin users.

This includes the Real World Evidence of FreeStyle Libre (RELIEF) retrospective study.

Findings from the trial showed that patients with type 2 diabetes who are on once-daily (basal) insulin had significant reductions in acute complications of diabetes, which led to a 67% decrease in hospitalisations.